Welcome to our dedicated page for Can-Fite BioPharma news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma stock.
Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Can-Fite (NYSE American: CANF) announced publication of a peer-reviewed article on Piclidenoson for canine osteoarthritis in Frontiers in Veterinary Science.
The study showed statistically significant improvements in mobility and pain with a favorable safety profile, supporting ongoing Phase 2 development and a Vetbiolix licensing deal potentially worth up to $325 million.
Can-Fite (NYSE American: CANF) plans a Phase 2b study of Namodenoson plus immunotherapy in advanced pancreatic cancer, following Phase 2a data showing a favorable safety profile, stable disease in >30% of evaluable patients, treatment beyond 16 months in a subset, and 35% remaining on therapy/follow-up.
Study design will be discussed at BIO International as Can-Fite advances partnership talks under confidentiality agreements.
Can-Fite (NYSE American: CANF) reported positive Phase 2a data for namodenoson in advanced pancreatic cancer on April 30, 2026. Key findings:
- Stable disease in >30% of evaluable patients
- 35% of patients remain on therapy, including one beyond 16 months
- Favorable safety and tolerability
Can-Fite (NYSE:CANF) announced that veterinary partner Vetbiolix completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of piclidenoson in 118 dogs with osteoarthritis. The 90-day, twice-daily oral study uses LOAD as the primary endpoint; top-line results are expected in Q3 2026.
Vetbiolix exercised its option to a full license and will fund development and regulatory activities; Can-Fite may receive upfront, milestone, and royalty payments totaling up to $325 million over the next decade, contingent on successful development and commercialization.
Can-Fite (NYSE American: CANF) reported 2025 results and clinical progress on March 26, 2026. Key clinical milestones include a Phase 2a pancreatic cancer study meeting its primary safety endpoint, a HCC patient alive and cancer-free >9 years after Namodenoson, and decompensated cirrhosis improvement leading to transplant.
2025 financials: revenues $0.41M (-40% YoY), R&D $6.69M (+16.3%), G&A $3.66M (+20.2%), net loss $9.83M. Company raised ~$4.3M from warrant exercises in March 2026.
Can-Fite (NYSE:CANF) announced that the Israeli Patent Office allowed patent No. 284463 for the use of A3 adenosine receptor agonists, including Namodenoson, to induce fat loss and treat obesity. The allowance expands global IP after prior grants in the US, Canada and Australia.
The company cited a peer-reviewed International Journal of Obesity study supporting Namodenoson’s anti-obesity effect and noted the global obesity therapeutics market is projected at $60.5 billion by 2030 (CAGR ~22%).
Can-Fite (NYSE American: CANF) entered a definitive agreement for immediate exercise of warrants to buy up to 795,869 ADSs at a reduced price of $5.00 per ADS (originally $9.34). Closing is expected on or about March 5, 2026, subject to customary conditions.
The company will issue new unregistered warrants to purchase up to 1,591,738 ADSs, exercisable at $5.00 until the 24-month anniversary of the Resale Registration Statement. Gross proceeds are expected to be approximately $4.0 million before placement agent fees and expenses. Net proceeds will fund R&D, clinical trials, working capital and general corporate purposes.
Can-Fite (NYSE American: CANF) reported that its Phase 2a open-label study of namodenoson in advanced pancreatic ductal adenocarcinoma met its primary endpoint of safety. The trial enrolled 20 heavily pretreated patients; namodenoson was very well tolerated with no new safety signals identified.
Survival follow-up is ongoing; one-third of patients were alive at data cut-off. Namodenoson holds FDA Orphan Drug Designation for pancreatic cancer and remains under further clinical evaluation.
Can-Fite (NYSE American: CANF) announced a peer-reviewed International Journal of Obesity publication (Feb 17, 2026) showing namodenoson reduced adipocyte proliferation and lipid accumulation in vitro and produced a statistically significant reduction in weight gain in a murine high-fat diet model after four weeks.
According to the company, findings align with prior Phase IIa MASH data showing reduced liver fat and body weight, highlight modulation of adiponectin and multiple metabolic pathways, note a favorable safety profile, and point to potential expansion into the growing obesity treatment market.
Can-Fite (NYSE American: CANF) announced the Canadian Patent Office issued a notice of allowance for Canadian Patent Application No. 3,126,002, covering Namodenoson for use as an anti-obesity therapy.
The allowance adds Canadian IP to existing U.S. and Australian obesity/metabolic patents, cites preclinical fat reduction and a MASH Phase IIa observation of 2.3% weight loss after 3 months with increased adiponectin, and highlights an excellent oral safety profile.